The Bone Cancer Research Trust's policy on working with pharmaceutical and medical device companies aims to provide clear principles and guidance about how we work with pharmaceutical companies and medical device companies to help achieve our aims and objectives.
Read our full policy here: Bone Cancer Research Trust Pharmaceutical Policy 2022
This policy was updated in July 2022.
For more information on this policy, contact us. If you work for a pharmaceutical company and would like to discuss how you could support us, please contact Rachel Wallace, Senior Trusts & Corporate Sponsorship Officer, on 07876 200 215.
Further details about the support we receive from pharmaceutical and medical device companies can be found below.
Support received in 2023
- Takeda £10,000 - Bone Cancer Conference 2023
- Leo Cancer Care £650 - Bone Cancer Conference 2023
Support received in 2022
- Takeda £10,000 - Bone Cancer Conference 2022
Support received in 2020
- Takeda £650 - Speaker's fee at conference
Support received in 2019
- Takeda £20,725 - Bone Cancer Conference 2019
Support received in 2018
- Takeda £16,995 - Bone Cancer Conference 2018
- Takeda £12,282 - Website support for patient information and support pages
Support received in 2017
- Takeda £15,000 - Bone Cancer Conference 2017
Support received in 2016
- None received
Support received in 2015
- None received
Support received in 2014
- Takeda £875 - For project input
- Implantcast £1,500 - Patients and Supporters Conference
- Takeda £5,000 - Research Strategy Meeting
- Takeda £5,000 - Patients and Supporters Conference
Support received in 2013
- None received
Support received in 2012
- Takeda £2,500 - Patients and Supporters Conference
Support received in 2011
- Takeda £5,000 - Patients and Supporters Conference
Support received in 2010
- Takeda £5,000 - Patients and Supporters Conference